Catalyst Pharmaceuticals — Business Overview

What does Catalyst Pharmaceuticals do?

Catalyst Pharmaceuticals is a small commercial-stage biopharmaceutical company focused on buying, developing, and selling treatments for rare and hard-to-treat diseases. Rather than discovering drugs from scratch, Catalyst acquires or licenses the rights to promising medicines and then markets them to patients in the United States. As of early 2026, the company has 182 employees, with 128 in its commercial organization.

Catalyst currently sells three drugs:

How does Catalyst Pharmaceuticals make money?

Catalyst's primary revenue comes from selling its two rare-disease drugs, FIRDAPSE® and AGAMREE®, directly to patients in the U.S. through specialty pharmacies. Because these are treatments for ultra-rare conditions (LEMS is estimated to affect roughly 3,600 to 5,400 Americans; DMD affects approximately 11,000 to 13,000), the drugs are distributed through a tightly controlled network of specialty pharmacies — primarily AnovoRx — rather than general retail chains. Prices for orphan drugs are typically high, and Catalyst supplements access with co-pay assistance programs that can reduce patient out-of-pocket costs to as little as $0 per month for commercially insured patients.

Beyond direct U.S. sales, Catalyst earns smaller streams of revenue from international sublicensing arrangements. For FIRDAPSE®, the company collects supply revenue, milestone payments, and royalties from sublicensees KYE Pharmaceuticals (Canada) and DyDo Pharma (Japan, commercially launched January 2025). AGAMREE® was similarly sublicensed to KYE for Canada, which received Health Canada approval in October 2025. These international streams are secondary to U.S. sales.

FYCOMPA® is winding down as a revenue contributor. Three generic tablet competitors and one generic oral suspension have already entered the U.S. market. Catalyst continues to sell the product but stopped all active marketing at year-end 2025, making this product a diminishing revenue source going forward.

What market does Catalyst Pharmaceuticals operate in?

Catalyst operates squarely in the rare (orphan) disease pharmaceutical market, focusing on conditions where fewer than 200,000 Americans are affected. LEMS has an estimated U.S. patient population of 3,600 to 5,400, roughly half of whom remain undiagnosed or misdiagnosed. DMD affects an estimated 11,000 to 13,000 Americans, with approximately 70% currently on corticosteroid treatment. These are tiny patient populations, but orphan drugs often command very high prices, and the FDA grants meaningful protections including seven-year orphan drug exclusivity (which bars competing products for the same indication) and various other exclusivity periods.

Secular trends favor this space. Regulatory incentives for orphan drug development — including expedited review pathways, tax credits, and exclusivity protections — have made rare diseases an attractive area for smaller biotech companies. Increased awareness of rare diseases, better genetic screening (the U.S. recently added DMD to its Recommended Uniform Screening Panel), and a growing number of disease advocacy organizations are gradually expanding the diagnosed patient population, which directly benefits companies like Catalyst.

Who are Catalyst Pharmaceuticals' main competitors?

The competitive landscape differs significantly by product. For FIRDAPSE® in LEMS, direct branded competition is limited — the main historical challenger was Jacobus Pharmaceutical's RUZURGI® (amifampridine), a dispute Catalyst resolved through a settlement and license in 2022 that effectively removed Jacobus as a competitor until at least 2034. The more pressing near-term threat is generic entry: three ANDA filers (Teva, Lupin, and Hetero) challenged FIRDAPSE® patents. Catalyst has since settled with Teva and Lupin, blocking their generic entry until February 2035. Litigation with Hetero remains ongoing, with a trial scheduled for March 2026 — the key near-term risk for FIRDAPSE®.

For AGAMREE® in DMD, the competitive field is busier and includes both branded and emerging gene therapy competitors:

• Emflaza® (deflazacort) — marketed by PTC Therapeutics, a traditional corticosteroid approved for DMD since 2017
• Duvyzat® (givinostat) — a non-steroidal anti-inflammatory approved in 2024 for DMD patients six and older
• Elevidys® — a gene therapy from Sarepta, currently restricted to ambulatory patients ages 4 and up; Catalyst acknowledges this could temporarily delay AGAMREE® use for some patients during gene therapy treatment, though it expects patients to return to a corticosteroid afterward
• Generic and compounded corticosteroids (prednisone, deflazacort) also remain widely used

Catalyst's claimed advantage for AGAMREE® is a differentiated mechanism — it acts on glucocorticoid and mineralocorticoid receptors in a way that is hoped to deliver similar efficacy to traditional steroids with a better side effect profile (particularly around bone health and growth in children).

Where does Catalyst Pharmaceuticals operate?

Catalyst is primarily a U.S.-focused business. Its commercial infrastructure — roughly 58 field sales personnel, 19 patient assistance liaisons, and 19 medical science liaisons — is entirely domestic, selling FIRDAPSE® and AGAMREE® through U.S. specialty pharmacies. The company holds $709.2 million in cash as of December 31, 2025, providing a strong domestic financial base.

International exposure exists but is handled through sublicensees, not direct operations. Catalyst does not operate sales forces outside the U.S. Instead, it collects milestone payments, supply revenue, and royalties from partners:

Catalyst also has rights to expand FIRDAPSE® into parts of Asia-Pacific and Central/South America under its amended license agreement, though no commercialization activity in those regions has been announced yet. Manufacturing is fully outsourced to contract manufacturers, with Catalyst transitioning AGAMREE® final goods manufacturing to a U.S. facility expected to be completed by 2026.